Funder: Breakthrough T1D
Due Dates: May 28, 2025 (Letter of Intent) | July 16, 2025 (Full proposal)
Funding Amounts: Up to $600,000 total costs over 2 years (SRAs); budgets above this require prior discussion.
Summary: Funding for technologies that address barriers to scaling next-generation islet cell therapies for type 1 diabetes, aiming to make these treatments broadly accessible and effective.